OMALIZUMAB IS COST-EFFECTIVE COMPARED TO STANDARD OF CARE IN UNCONTROLLED SEVERE ALLERGIC ASTHMA PATIENTS

被引：0
|
作者：
Kaur, H. [1 ]
Dongare, S. [1 ]
Lijie, W. [2 ]
Alvares, L. [3 ]
机构：
[1] Novartis Healthcare Pvt Ltd, Hyderabad, Telangana, India
[2] Novartis Pharma China, Shanghai, Peoples R China
[3] Novartis Pharma AG, Basel, Switzerland
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.07.790
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRS17
引用
收藏
页码：S104 / S104
页数：1
相关论文
共 50 条
  • [1] OMALIZUMAB FOR SEVERE ALLERGIC ASTHMA: COST-EFFECTIVE OR PRICELESS?
    Miles, J.
    Green, D.
    THORAX, 2011, 66 : A111 - A112
  • [2] Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy
    Odajima, Hiroshi
    Ebisawa, Motohiro
    Nagakura, Toshikazu
    Fujisawa, Takao
    Akasawa, Akira
    Ito, Komei
    Doi, Satoru
    Yamaguchi, Koichi
    Katsunuma, Toshio
    Kurihara, Kazuyuki
    Kondo, Naomi
    Sugai, Kazuko
    Nambu, Mitsuhiko
    Hoshioka, Akira
    Yoshihara, Shigemi
    Sato, Norio
    Seko, Noriko
    Nishima, Sankei
    ALLERGOLOGY INTERNATIONAL, 2015, 64 (04) : 364 - 370
  • [3] Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting
    Suzuki, Cibele
    da Silva, Nilceia Lopes
    Kumar, Praveen
    Pathak, Purnima
    Ong, Siew Hwa
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (08) : 832 - 839
  • [4] Cost-Effectiveness Of Tiotropium Versus Omalizumab For Patients With Severe Uncontrolled Allergic Asthma In Us
    Zafari, Z.
    Fitzgerald, M.
    Marra, C.
    Sadatsafavi, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [5] COST-EFFECTIVENESS ANALYSIS OF OMALIZUMAB COMPARED WITH STANDARD OF CARE FOR SEVERE ALLERGIC ASTHMA BASED ON REAL WORLD EVIDENCE IN JAPAN
    Muthukumar, M.
    Kozawa, M.
    Alvares, L.
    Milligan, K.
    Igarashi, A.
    VALUE IN HEALTH, 2018, 21 : S104 - S105
  • [6] COST-EFFECTIVENESS ANALYSIS OF OMALIZUMAB IN THE TREATMENT OF UNCONTROLLED SEVERE ALLERGIC ASTHMA IN CHINA
    Zhu, S.
    Xiao, D.
    Wang, L.
    Xuan, J.
    VALUE IN HEALTH, 2019, 22 : S49 - S49
  • [7] Influence of Genetics on the Response to Omalizumab in Patients with Severe Uncontrolled Asthma with an Allergic Phenotype
    Rojo-Tolosa, Susana
    Sanchez-Martinez, Jose Antonio
    Pineda-Lancheros, Laura Elena
    Galvez-Navas, Jose Maria
    Gonzalez-Gutierrez, Maria Victoria
    Jimenez-Galvez, Gonzalo
    Perez-Ramirez, Cristina
    Morales-Garcia, Concepcion
    Jimenez-Morales, Alberto
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (08)
  • [8] Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients
    Arrobas, A.
    Barbosa, M. P.
    Rabiais, S.
    Vandewalle, B.
    Felix, J.
    PULMONOLOGY, 2021, 27 (02): : 124 - 133
  • [9] Incremental cost-effective ratio effect of Omalizumab treatment for Severe Allergic Asthma at Danish university Hospital.
    Petersen, Soren Bagge
    Weincreich, Ulla Moller
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [10] Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma
    Brown, R.
    Turk, F.
    Dale, P.
    Bousquet, J.
    ALLERGY, 2007, 62 (02) : 149 - 153
12345